GRI Bio
La Jolla
About GRI Bio
GRI Bio is a biotechnology company that develops therapies to treat inflammatory diseases. Its cell-based therapies are developed to treat liver disease and autoimmunity deficiencies by targeting the regulation of NKT cells.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $27.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2025)
- Ticker: nasdaq:GRI
- Website: gribio.com
- Phone: (619) 400-1171
Industries & Categories
Biopharma, Biotechnology, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/gri-bio-24791 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.